6770 | ||
(State or other jurisdiction of incorporation or organization) | (Primary Standard Industrial Classification Code Number) | (I.R.S. Employer Identification No.) |
Large accelerated filer | ☐ | Accelerated filer | ☐ |
☒ | Smaller reporting company | ||
Emerging growth company |
PRELIMINARY PROSPECTUS | SUBJECT TO COMPLETION | DATED APRIL 15, 2025 |
Page | |
ABOUT THIS PROSPECTUS ......................................................................................................................... | |
PROSPECTUS SUMMARY ............................................................................................................................ | |
RISK FACTORS .............................................................................................................................................. | |
USE OF PROCEEDS ....................................................................................................................................... | |
OF OPERATIONS ...................................................................................................................................... | |
BUSINESS ........................................................................................................................................................ | |
MANAGEMENT .............................................................................................................................................. | |
EXECUTIVE AND DIRECTOR COMPENSATION OF INNVENTURE .................................................... | |
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS ............................................... | |
DESCRIPTION OF SECURITIES ................................................................................................................... | |
DESCRIPTION OF INNVENTURE WARRANTS ........................................................................................ | |
SELLING STOCKHOLDERS ......................................................................................................................... | |
SHARES ELIGIBLE FOR FUTURE SALE .................................................................................................... | |
PLAN OF DISTRIBUTION ............................................................................................................................. | |
EXPERTS ......................................................................................................................................................... | |
LEGAL MATTERS .......................................................................................................................................... | |
WHERE YOU CAN FIND MORE INFORMATION ..................................................................................... | |
INDEX TO FINANCIAL STATEMENTS ...................................................................................................... |
Issuer ........................................................................ | Innventure, Inc. |
Shares of Common Stock to be issued upon exercise of the Innventure Warrants ........................ | 18,386,688 |
Shares of Common Stock that may be offered and sold from time to time by the Selling Stockholders named herein or their permitted transferees ........................................................... | Up to 15,965,989 shares of Common Stock, which includes (i) up to 8,480,518 shares of Common Stock that may be issued upon conversion of Series C Preferred Stock, (ii) 85,471 shares of Common Stock issued to Ducera, (iii) up to 3,000,000 shares of Common Stock that may be issued upon the conversion of Convertible Debentures issued to Yorkville pursuant to the Securities Purchase Agreement, (iv) up to 4,100,000 shares of Common Stock that we may issue and sell to Yorkville from time to time pursuant to the SEPA (without exceeding the Exchange Cap) and (v) 300,000 shares of Common Stock that may be issued upon exercise of the 2025 WTI Warrants. |
Shares of Common Stock outstanding ..................... | 47,106,300 (as of April 11, 2025) |
Use of proceeds ........................................................ | We will not receive any of the proceeds from such sales of the shares of our Common Stock by the Selling Stockholders. However, we may receive (i) up to $75.0 million in aggregate gross proceeds from sales of shares of Common Stock to Yorkville pursuant to the SEPA, from time to time in our discretion after the date of the registration statement that includes this prospectus and subject to satisfaction of other conditions in the SEPA, and (ii) de minimis gross proceeds upon exercise of the 2025 WTI Warrants, to the extent such warrants are exercised for cash. Additionally, we could receive up to an aggregate of approximately $214.4 million in proceeds from the exercise of the Innventure Warrants, assuming the exercise in full of all of the Innventure Warrants for cash. We believe the likelihood that warrant holders will exercise their Innventure Warrants, and therefore the amount of cash proceeds that we would receive, is dependent upon the market price of our Common Stock. As of the date of this prospectus, all of the Innventure Warrants are “out of the money,” meaning the exercise price is higher than the market price of our Common Stock. Holders of such “out of the money” Innventure Warrants are not likely to exercise such Innventure Warrants. We will not receive any proceeds from the exercise of 2025 WTI Warrants or Innventure Warrants on a cashless basis. We will bear all costs, expenses and fees in connection with the registration of our Common Stock hereunder. The Selling Stockholders will bear all commissions, discounts and certain other limited expenses, if any, attributable to their respective sales of our Common Stock. Unless we inform you otherwise in a prospectus supplement or free writing prospectus, we intend to use the net proceeds from the issuance of shares to Yorkville pursuant to the SEPA, the exercise of the 2025 WTI Warrants and the exercise of the Innventure Warrants for general corporate purposes, which may include acquisitions or other strategic investments or repayment of outstanding indebtedness. |
Exercise price of 2025 WTI Warrants ..................... | $0.01 per share of Common Stock |
Exercise price of Innventure Warrants ..................... | $11.50 per share of Common Stock |
NASDAQ Global Market symbol ............................ | “INV” |
Risk factors .............................................................. | Investing in our Common Stock involves a high degree of risk. information in this prospectus for a discussion of the factors you should consider carefully before you decide to invest in our Common Stock. |
Successor | Predecessor | S/P Combined (Non-GAAP) | Predecessor | Non-GAAP | ||||||||
Period from October 2, 2024 through December 31, 2024 | Period from January 1, 2024 through October 1, 2024 | Year ended December 31, 2024 | Year ended December 31, 2023 | 2024 vs 2023 Changes | ||||||||
($) | ($) | ($) | ($) | ($) | (%) | |||||||
Revenue | 456 | 764 | 1,220 | 1,117 | 103 | 9.2% | ||||||
Operating Expenses | ||||||||||||
Cost of sales ........................................................ | 3,752 | 777 | 4,529 | — | 4,529 | nil | ||||||
General and administrative ................................. | 29,652 | 26,608 | 56,260 | 17,589 | 38,671 | 219.9% | ||||||
Sales and marketing ............................................ | 2,009 | 4,178 | 6,187 | 3,205 | 2,982 | 93.0% | ||||||
Research and development ................................. | 5,340 | 5,978 | 11,318 | 4,001 | 7,317 | 182.9% | ||||||
Total Operating Expenses | 40,753 | 37,541 | 78,294 | 24,795 | 53,499 | 215.8% | ||||||
Loss from Operations | (40,297) | (36,777) | (77,074) | (23,678) | (53,396) | 225.5% | ||||||
Non-operating (Expense) and Income | ||||||||||||
Interest expense, net ........................................... | (1,132) | (1,300) | (2,432) | (1,224) | (1,208) | 98.7% | ||||||
Net gain (loss) from investments ........................ | — | 11,547 | 11,547 | (6,448) | 17,995 | 279.1% | ||||||
Net (loss) gain on investments - due to related parties .................................................................. | — | (468) | (468) | 232 | (700) | (301.7)% | ||||||
Change in fair value of financial liabilities ......... | (20,946) | (478) | (21,424) | 766 | (22,190) | (2,896.9)% | ||||||
Equity method investment (loss) income ........... | (902) | 893 | (9) | (632) | 623 | (98.6)% | ||||||
Loss on conversion of promissory notes ............ | — | (1,119) | (1,119) | — | (1,119) | nil | ||||||
Write-off of loan commitment fee asset ............. | (10,041) | — | (10,041) | — | (10,041) | nil | ||||||
Miscellaneous other expense .............................. | (57) | (64) | (121) | — | (121) | nm* | ||||||
Total Non-operating (Expense) Income | (33,078) | 9,011 | (24,067) | (7,306) | (16,761) | 229.4% | ||||||
Income tax expense (benefit) | (3,282) | 432 | (2,850) | — | (2,850) | nm* | ||||||
Net Loss | (70,093) | (28,198) | $(98,291) | (30,984) | (67,307) | 217.2% | ||||||
Less: net loss attributable to | ||||||||||||
Non-redeemable non-controlling interest ........... | (8,339) | (11,762) | $(20,101) | (139) | (19,962) | 14,361.2% | ||||||
Net Loss Attributable to Innventure, Inc. Stockholders / Innventure LLC Unitholders | (61,754) | (16,436) | (78,190) | (30,845) | (47,345) | 153.5% | ||||||
Other comprehensive income, net of taxes: | ||||||||||||
Unrealized gain on available-for-sale debt securities - related party ...................................... | 909 | 62 | 971 | — | 971 | nil | ||||||
Total other comprehensive loss, net of taxes | 909 | 62 | $971 | — | 971 | nil | ||||||
Total comprehensive loss, net of taxes | (69,184) | (28,136) | (97,320) | (30,984) | (66,336) | 214.1% | ||||||
Less: comprehensive income attributable to | ||||||||||||
Non-redeemable non-controlling interest ........... | (8,339) | (11,762) | (20,101) | (139) | (19,962) | 14,361.2% | ||||||
Net Comprehensive Loss Attributable to Innventure, Inc. Stockholders / Innventure LLC Unitholders | (60,845) | (16,374) | (77,219) | (30,845) | (46,374) | 150.3% |
Successor | Predecessor | S/P Combined (Non-GAAP) | Predecessor | ||||||
Period from October 2, 2024 through December 31, 2024 | Period from January 1, 2024 through October 1, 2024 | Year ended December 31, 2024 | Year ended December 31, 2023 | ||||||
Net Loss ............................................................ | (70,093) | (28,198) | (98,291) | (30,984) | |||||
Interest expense, net(1) ...................................... | 11,173 | 1,300 | 12,473 | 1,224 | |||||
Depreciation and amortization expense ............ | 5,455 | 146 | 5,601 | 8 | |||||
Provision for income taxes ............................... | 3,282 | (432) | 2,850 | — | |||||
EBITDA ........................................................... | (50,183) | (27,184) | (77,367) | (29,752) | |||||
Transaction and other related costs(2) ............... | 2,309 | 9,414 | 11,723 | 3,452 | |||||
Change in fair value of financial liabilities(3) ... | 20,946 | 478 | 21,424 | (766) | |||||
Stock based compensation(4) ............................. | 16,338 | 1,056 | 17,394 | 910 | |||||
Adjusted EBITDA .......................................... | (10,590) | (16,236) | (26,826) | (26,156) |
Successor | Predecessor | ||||
December 31, 2024 | December 31, 2023 | ||||
Cash and cash equivalents ....................................................................................... | $11,119 | $2,475 | |||
Restricted cash ......................................................................................................... | — | 100 | |||
Working capital ....................................................................................................... | (45,061) | (2,504) | |||
Accumulated deficit ................................................................................................ | $(78,262) | $(64,284) |
Successor | Predecessor | S/P Combined 2024 | Predecessor | Change | |||||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2024 | Year ended December 31, 2023 | Amount | % Change | ||||||
Net Cash Used in Operating Activities ............................................. | $( | $( | $(48,062) | $( | $(28,586) | 146.8% | |||||
Net Cash Provided by (Used in) Investing Activities ............................. | ( | 865 | ( | 5,532 | 118.5% | ||||||
Net Cash Provided by Financing Activities ............................................. | 71,907 | 52,733 | 275.0% | ||||||||
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash .................................................... | $ | $ | $24,710 | $( | $29,679 | (597.3)% |
2025 | 2026 | 2027 | 2028 | Thereafter | Total | ||||||
Operating lease .............................................. | 299 | 351 | 94 | — | — | 744 | |||||
Debt obligations ............................................ | 14,625 | 7,295 | 8,244 | 4,561 | — | 34,725 | |||||
Total .............................................................. | 14,924 | 7,646 | 8,338 | 4,561 | — | 35,469 |
Committee Assignments | |||||||||||||||||
Donnally | Brown | Williams | Hennessy | Amalfitano | Haskell* | Yablunosky* | Otworth* | Niemeyer* | |||||||||
Audit ........................ | C | X | X | ||||||||||||||
Compensation ......... | X | C | X | ||||||||||||||
N&CG ..................... | X | X | C |
Name and Principal Position | Fiscal Year | Salary ($)(1) | Bonus ($)(2) | Stock Awards ($)(3) | Option Awards ($)(4) | Non-Equity Incentive Plan Compensation ($) | All Other Compensation ($)(5) | Total ($) | ||||||||
Gregory W. (Bill) Haskell ................... | 2024 | 300,000 | 2,500,000 | — | — | — | 13,800 | 2,813,800 | ||||||||
Chief Executive Officer .................... | 2023 | 300,000 | 180,000 | — | — | — | 12,000 | 492,000 | ||||||||
Mike Otworth ............. | 2024 | 300,000 | — | 7,001,001 | 7,577,786 | — | — | 14,878,787 | ||||||||
Executive Chairman(6) | 2023 | 300,000 | 180,000 | — | — | — | — | 480,000 | ||||||||
Dr. John Scott ............. | 2024 | 300,000 | — | 4,100,005 | 6,935,489 | — | — | 11,335,494 | ||||||||
Chief Strategy Officer(7) ................. | 2023 | 300,000 | 180,000 | — | — | — | — | 480,000 |
NEO | 2024 Base Salary/Service Fee Rate | |
Gregory Haskell ................................................................................................................................... | $300,000 | |
Mike Otworth ....................................................................................................................................... | $300,000 | |
Dr. John Scott ...................................................................................................................................... | $300,000 |
2024 Bonus Goal | Weighting | Goal Achieved? (yes or no) | ||
Formation of a new (4th) operating company .......................................................... | 25% | Yes | ||
Complete the Business Combination with more than $20 million of net proceeds . | 50% | Yes | ||
Meeting each of the following milestones (or a achieving a certain threshold share price): | ||||
•Formation of a new (4th) operating company ................................................... | 10% | Yes | ||
•$10 million of booked revenue for Accelsius ................................................... | 10% | No | ||
•$15 million of GAAP revenue for AeroFlexx ................................................... | 5% | No |
NEO | RSUs | Options* | ||
Gregory Haskell ....................................................................................................... | — | — | ||
Mike Otworth ........................................................................................................... | 537,705 | 262,295 | ||
Dr. John Scott ........................................................................................................... | 336,066 | 163,934 |
Name | Grant Date | Number of securities underlying the award | Exercise price of the award ($/ Sh) | Grant date fair value of the award | Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information | |||||
Gregory Haskell, CEO ...... | — | — | — | — | — | |||||
Mike Otworth, Executive Chairman ........................... | 12/9/2024 | 262,295 | 12.20 | $1,712,786 | (0.88)% | |||||
Dr. John Scott, Chief Strategy Officer ................. | 12/9/2024 | 163,934 | 12.20 | $1,070,489 | (0.88)% |
Option Awards | Stock Awards | ||||||||||||||||
Name | Type of Award(1) | Number of Securities Underlying Unexercised Options (#) Exercisable | Number of Securities Underlying Unexercised Options (#) Unexercisable | Option Exercise Price ($) | Option Expiration Date | Number of Shares or Units of Stock That Have Not Vested (#) | Market Value of Shares or Units of Stock That Have Not Vested ($) | ||||||||||
Gregory W. (Bill) Haskell .... | Refinity Units | — | — | — | — | 109,000 | (4) | — | |||||||||
Mike Otworth ....................... | INV Options | — | 262,295 | (2) | 12.20 | 12/9/2034 | |||||||||||
Refinity Units | 109,000 | (4) | — | ||||||||||||||
Accelsius SARs | — | 150,000 | (3) | 12.175 | 12/31/2026 | ||||||||||||
INV RSUs | 537,705 | (5) | 7,447,214 | ||||||||||||||
Accelsius Units | 75,000 | (6) | 3,147,750 | (7) | |||||||||||||
Dr. John Scott ....................... | INV Options | — | 163,934 | (2) | 12.20 | 12/9/2034 | |||||||||||
Refinity Units | 109,000 | (4) | — | ||||||||||||||
Accelsius SARs | — | 150,000 | (3) | 12.175 | 12/31/2026 | ||||||||||||
INV RSUs | 336,066 | (5) | 4,654,514 | ||||||||||||||
Accelsius Units | — | — | — | — | 9,375 | (8) | 434,813 | (7) |
Name | Fees earned or paid in cash ($) | Stock awards ($)(1) | Option awards ($)(2) | Total ($) | ||||
James Donnally ............................................... | 27,500 | 89,999 | 782,000 | 899,499 | ||||
Bruce Brown .................................................... | 27,500 | 89,999 | — | 117,499 | ||||
Elizabeth Williams .......................................... | 25,000 | 89,999 | — | 114,999 | ||||
Daniel Hennessy .............................................. | 25,000 | 89,999 | — | 114,999 | ||||
Michael Amalfitano ........................................ | 25,000 | 89,999 | — | 114,999 |
Company Name | Fiscal Year Ended December 31, | |||
2024 | 2023 | |||
Accelsius ................................................................................................................. | $126 | 160 | ||
AeroFlexx ............................................................................................................... | * | * | ||
ESG Fund ............................................................................................................... | * | * | ||
Refinity ................................................................................................................... | $539 | * |
Fair Market Value of Common Stock (per share) | ||||||||||||||||||
Redemption Date (period to expiration of warrants) | ≤10.00 | 11.00 | 12.00 | 13.00 | 14.00 | 15.00 | 16.00 | 17.00 | ≥18.00 | |||||||||
60 months .............. | 0.261 | 0.281 | 0.297 | 0.311 | 0.324 | 0.337 | 0.348 | 0.358 | 0.361 | |||||||||
57 months .............. | 0.257 | 0.277 | 0.294 | 0.310 | 0.324 | 0.337 | 0.348 | 0.358 | 0.361 | |||||||||
54 months .............. | 0.252 | 0.272 | 0.291 | 0.307 | 0.322 | 0.335 | 0.347 | 0.357 | 0.361 | |||||||||
51 months .............. | 0.246 | 0.268 | 0.287 | 0.304 | 0.320 | 0.333 | 0.346 | 0.357 | 0.361 | |||||||||
48 months .............. | 0.241 | 0.263 | 0.283 | 0.301 | 0.317 | 0.332 | 0.344 | 0.356 | 0.361 | |||||||||
45 months .............. | 0.235 | 0.258 | 0.279 | 0.298 | 0.315 | 0.330 | 0.343 | 0.356 | 0.361 | |||||||||
42 months .............. | 0.228 | 0.252 | 0.274 | 0.294 | 0.312 | 0.328 | 0.342 | 0.355 | 0.361 | |||||||||
39 months .............. | 0.221 | 0.246 | 0.269 | 0.290 | 0.309 | 0.325 | 0.340 | 0.354 | 0.361 | |||||||||
36 months .............. | 0.213 | 0.239 | 0.263 | 0.285 | 0.305 | 0.323 | 0.339 | 0.353 | 0.361 | |||||||||
33 months .............. | 0.205 | 0.232 | 0.257 | 0.280 | 0.301 | 0.320 | 0.337 | 0.352 | 0.361 | |||||||||
30 months .............. | 0.196 | 0.224 | 0.250 | 0.274 | 0.297 | 0.316 | 0.335 | 0.351 | 0.361 | |||||||||
27 months .............. | 0.185 | 0.214 | 0.242 | 0.268 | 0.291 | 0.313 | 0.332 | 0.350 | 0.361 | |||||||||
24 months .............. | 0.173 | 0.204 | 0.233 | 0.260 | 0.285 | 0.308 | 0.329 | 0.348 | 0.361 | |||||||||
21 months .............. | 0.161 | 0.193 | 0.223 | 0.252 | 0.279 | 0.304 | 0.326 | 0.347 | 0.361 | |||||||||
18 months .............. | 0.146 | 0.179 | 0.211 | 0.242 | 0.271 | 0.298 | 0.322 | 0.345 | 0.361 | |||||||||
15 months .............. | 0.130 | 0.164 | 0.197 | 0.230 | 0.262 | 0.291 | 0.317 | 0.342 | 0.361 | |||||||||
12 months .............. | 0.111 | 0.146 | 0.181 | 0.216 | 0.250 | 0.282 | 0.312 | 0.339 | 0.361 | |||||||||
9 months ................ | 0.090 | 0.125 | 0.162 | 0.199 | 0.237 | 0.272 | 0.305 | 0.336 | 0.361 | |||||||||
6 months ................ | 0.065 | 0.099 | 0.137 | 0.178 | 0.219 | 0.259 | 0.296 | 0.331 | 0.361 | |||||||||
3 months ................ | 0.034 | 0.065 | 0.104 | 0.150 | 0.197 | 0.243 | 0.286 | 0.326 | 0.361 | |||||||||
0 months ................ | — | — | 0.042 | 0.115 | 0.179 | 0.233 | 0.281 | 0.323 | 0.361 |
Name and Address of Beneficial Owner | Amount and Nature of Beneficial Ownership | Percentage of Outstanding Shares | ||
Directors and Named Executive Officers: | ||||
Roland Austrup ......................................................................................................... | 863,264 | 1.83% | ||
James O. Donnally(1) ................................................................................................ | 4,224,536 | 8.97% | ||
Gregory W. Haskell .................................................................................................. | 752,115 | 1.60% | ||
Michael Otworth(2) .................................................................................................... | 2,942,912 | 6.22% | ||
John Scott(3) .............................................................................................................. | 2,081,653 | 4.38% | ||
David Yablunosky .................................................................................................... | 185,871 | * | ||
Suzanne Niemeyer .................................................................................................... | 153,005 | * | ||
Bruce Brown ............................................................................................................. | — | * | ||
Elizabeth Williams ................................................................................................... | — | * | ||
Daniel J. Hennessy ................................................................................................... | 1,170,262 | 2.48% | ||
Michael Amalfitano .................................................................................................. | — | * | ||
All Directors and Executive Officers as a Group (11 Individuals) | 12,373,608 | 25.73% | ||
Five Percent Holders | ||||
WE-INN LLC(4) ........................................................................................................ | 8,697,656 | 18.46% | ||
Ascent X Innventure TC, A Series of Ascent X Innventure, LP(5) ........................... | 3,541,685 | 7.48% | ||
CastleKnight Master Fund LP(6) ............................................................................... | 3,953,354 | 8.39% | ||
Glockner Family Venture Fund, LP(7) ...................................................................... | 4,680,272 | 9.17% |
Name of Selling Stockholder | Number of Shares of Common Stock Beneficially Owned Prior to Offering | Maximum Number of Shares of Common Stock to be Sold Pursuant to this Prospectus | Number of Shares of Common Stock Beneficially Owned After Offering | Percent of Common Stock Beneficially Owned After Offering | ||||
Holders of Series C Preferred Stock | ||||||||
Ascent X Innventure TC, A Series of Ascent X Innventure, LP ......................... | 3,541,685(1) | 367,333(2) | 3,291,685 | 6.9% | ||||
Casata Investments LLC ............................... | 200,000(3) | 293,866(2) | — | * | ||||
Crown Global Life Insurance LTD IRO Separate Account 30286 .......................... | 100,0004) | 146,933(2) | — | * | ||||
Glockner Family Venture Fund, LP .............. | 4,680,272(5) | 5,790,190(2) | 739,566 | 1.4% | ||||
Grail Partners LLC ........................................ | 429,524(6) | 587,732(2) | 29,524 | * | ||||
John Scott ...................................................... | 2,081,653(7) | 665,118(2) | 1,628,985 | 3.4% | ||||
Michael Otworth ........................................... | 2,942,902(8) | 335,480(2) | 2,714,580 | 5.7% | ||||
Neil Eichlberger 2021 Irrevocable Trust ...... | 200,000(9) | 293,866(2) | — | * | ||||
Convertible Debentures and SEPA | ||||||||
YA II PN, Ltd. .............................................. | 2,000,000(10) | 7,100,000(11) | — | * | ||||
Other | ||||||||
Ducera Securities LLC(12) ............................. | 85,471 | 85,471 | — | * | ||||
WTI Fund X, LLC ........................................ | 975,000 | 225,000(13) | 750,000 | 1.6% | ||||
WTI Fund XI, LLC ....................................... | 325,000 | 75,000(14) | 250,000 | * |
Consolidated Financial Statements | Page No. | |
Consolidated Balance Sheets as of December 31, 2024 and 2023 .............................................................. | ||
ended December 31, 2023 (Predecessor) ................................................................................................. | ||
31, 2023 (Predecessor) ............................................................................................................................. | ||
Notes to Consolidated Financial Statements ............................................................................................... |
Successor | Predecessor | |||
December 31, 2024 | December 31, 2023 | |||
Assets | ||||
Cash, cash equivalents and restricted cash .......................................................... | $ | $ | ||
Accounts receivable ............................................................................................. | ||||
Due from related parties ...................................................................................... | ||||
Inventories ........................................................................................................... | ||||
Prepaid expenses and other current assets ........................................................... | ||||
Total Current Assets ............................................................................................ | ||||
Investments .......................................................................................................... | ||||
Property, plant and equipment, net ...................................................................... | ||||
Intangible assets, net ............................................................................................ | ||||
Goodwill .............................................................................................................. | ||||
Other assets .......................................................................................................... | ||||
Total Assets ........................................................................................................... | $ | $ | ||
Liabilities and Stockholders' Deficit | ||||
Accounts payable ................................................................................................. | $ | $ | ||
Accrued employee benefits ................................................................................. | ||||
Accrued expenses ................................................................................................ | ||||
Related party payables ......................................................................................... | ||||
Related party notes payable - current .................................................................. | ||||
Notes payable - current ........................................................................................ | ||||
Patent installment payable - current .................................................................... | ||||
Obligation to issue equity .................................................................................... | ||||
Warrant liability ................................................................................................... | ||||
Other current liabilities ........................................................................................ | ||||
Total Current Liabilities ....................................................................................... | ||||
Notes payable, net of current portion .................................................................. | ||||
Convertible promissory note, net ......................................................................... | ||||
Convertible promissory note due to related party, net ......................................... | ||||
Embedded derivative liability .............................................................................. | ||||
Earnout liability ................................................................................................... | ||||
Stock-based compensation liability ..................................................................... | ||||
Patent installment payable, net of current ............................................................ | ||||
Deferred income taxes ......................................................................................... | ||||
Other liabilities .................................................................................................... | ||||
Total Liabilities ...................................................................................................... | ||||
Commitments and Contingencies (Note 19) | ||||
Mezzanine Capital | ||||
Redeemable Class I Units, no par value, and outstanding as of December 31, 2023 ....................................................... | ||||
Redeemable Class PCTA Units, no par value, issued and outstanding as of December 31, 2023 ............................................ | ||||
Stockholders' Equity / Unitholders' Deficit | ||||
Class B Preferred Units, no par value, | — |
Successor | Predecessor | |||
December 31, 2024 | December 31, 2023 | |||
Class B-1 Preferred Units, no par value, | — | |||
Class A Units, no par value, units issued and outstanding as of December 31, 2023 ................................... | — | |||
Class C Units, no par value, issued and outstanding as of December 31, 2023 ............................................ | — | |||
Preferred Stock, $ | — | |||
Common Stock, $ | — | |||
Additional paid-in capital .................................................................................... | ||||
Accumulated other comprehensive gain (loss) .................................................... | ||||
Accumulated deficit ............................................................................................. | ( | ( | ||
Total Innventure, Inc., Stockholders’ Equity/ Innventure LLC Unitholders' Deficit ................................................................................................................... | ( | |||
Non-controlling interest ....................................................................................... | ||||
Total Stockholders' Equity/ Unitholders' Deficit ............................................... | ( | |||
Total Liabilities, Mezzanine Capital and Equity ................................................ | $ | $ |
Predecessor | ||||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Revenue ..................................................................................... | $ | $ | $ | |||
Operating Expenses | ||||||
Cost of sales .......................................................................... | ||||||
General and administrative ................................................... | ||||||
Sales and marketing .............................................................. | ||||||
Research and development .................................................... | ||||||
Total Operating Expenses ...................................................... | ||||||
Loss from Operations ............................................................. | ( | ( | ( | |||
Non-operating (Expense) and Income | ||||||
Interest expense, net .............................................................. | ( | ( | ( | |||
Net gain (loss) from investments .......................................... | ( | |||||
Net (loss) gain on investments - due to related parties ......... | ( | |||||
Change in fair value of financial liabilities ........................... | ( | ( | ||||
Equity method investment (loss) income .............................. | ( | ( | ||||
Loss on conversion of promissory notes ............................... | ( | |||||
Write-off of loan commitment fee asset ............................... | ( | |||||
Miscellaneous other expense ................................................ | ( | ( | ||||
Total Non-operating (Expense) Income ............................... | ( | ( | ||||
Loss before Income Taxes ....................................................... | ( | ( | ( | |||
Income tax expense (benefit) ................................................ | ( | |||||
Net Loss ................................................................................... | ( | ( | ( | |||
Less: net loss attributable to | ||||||
Non-redeemable non-controlling interest ............................. | ( | ( | ( | |||
Net Loss Attributable to Innventure, Inc. Stockholders / Innventure LLC Unitholders ............................................. | ( | ( | ( | |||
Basic and diluted loss per share ............................................ | $( | |||||
Basic and diluted weighted average common shares ............ | ||||||
Other comprehensive income, net of taxes: | ||||||
Unrealized gain on available-for-sale debt securities - related party ....................................................................... | ||||||
Total other comprehensive loss, net of taxes ......................... | ||||||
Total comprehensive loss, net of taxes ................................... | ( | ( | ( | |||
Less: comprehensive income attributable to ......................... | ||||||
Non-redeemable non-controlling interest ............................. | ( | ( | ( | |||
Net Comprehensive Loss Attributable to Innventure, Inc. Stockholders / Innventure LLC Unitholders ..................... | $( | $( | $( |
Class I Amount | Class PCTA Amount | Total | |||
December 31, 2022 ....................................................................... | $ | $ | $ | ||
Proceeds from capital calls to unitholders ................................. | |||||
Accretion of redeemable units to redemption value .................. | ( | ( | ( | ||
December 31, 2023 ....................................................................... | |||||
Accretion of redeemable units to redemption value .................. | |||||
October 1, 2024 ............................................................................. | $ | $ | $ |
Class B Preferred | Class B-1 Preferred | Class A | Class C | Accumulated Deficit | Accumulated OCI | Non- Controlling Interest | Total Unitholders' Deficit | ||||||||
December 31, 2022 (Predecessor) .............. | $ | $ | $ | $ | $( | $ | $ | $( | |||||||
Net loss ..................................................... | — | — | — | — | ( | — | ( | ( | |||||||
Non-controlling interest acquired ............ | — | — | — | — | — | — | |||||||||
Issuance of units, net of issuance costs .... | — | — | — | — | — | — | |||||||||
Unit-based compensation ......................... | — | — | — | — | — | ||||||||||
Distributions to unitholders ...................... | — | — | — | — | ( | — | — | ( | |||||||
Accretion of redeemable units to redemption value .................................. | — | — | — | — | — | — | |||||||||
December 31, 2023 (Predecessor) .............. | ( | ( | |||||||||||||
Net loss ..................................................... | — | — | — | — | ( | — | ( | ( | |||||||
Other comprehensive loss, net of taxes .... | — | — | — | — | — | — | |||||||||
Units issued to non-controlling interest ... | — | — | — | — | — | — | |||||||||
Issuance of units, net of issuance costs .... | — | — | — | — | — | — | |||||||||
Unit-based compensation ......................... | — | — | — | — | — | ||||||||||
Issuance of units to non-controlling interest in exchange of convertible promissory notes .................................. | — | — | — | — | — | — | |||||||||
Accretion of redeemable units to redemption value .................................. | — | — | — | — | ( | — | — | ( | |||||||
October 1, 2024 (Predecessor) ................... | $ | $ | $ | $ | $( | $ | $ | $( |
Series B Preferred Stock | Common Stock | ||||||||||||||||
Shares | Amount | Shares | Amount | Additional Paid-In Capital | Accumulated Deficit | Accumulated OCI | Non- Controlling Interest | Total Stockholders' Equity | |||||||||
October 2, 2024 (Successor) .......... | $ | $ | $ | $( | $ | $ | $( | ||||||||||
Effect of acquisition of Innventure LLC ....................... | — | — | — | — | |||||||||||||
Reclassification of warrants from liability to equity ...................... | — | — | — | — | — | — | — | ||||||||||
Issuance of common shares, net of issuance costs ...................... | — | — | — | — | — | — | |||||||||||
Issuance of preferred shares, net of issuance costs ...................... | — | — | — | — | — | — | |||||||||||
Issuance of common shares from warrant exercises ..................... | — | — | — | — | — | — | |||||||||||
Net loss ........................................ | — | — | — | — | — | ( | — | ( | ( | ||||||||
Other comprehensive gain, net of taxes ......................................... | — | — | — | — | — | — | — | ||||||||||
Non-controlling interest acquired | — | — | — | — | — | — | — | ||||||||||
Distributions to Stockholders ...... | — | — | — | — | — | ( | — | — | ( | ||||||||
Vesting of contingent at risk sponsor shares .......................... | — | — | — | — | — | — | — | — | |||||||||
Stock-based compensation .......... | — | — | — | — | — | — | |||||||||||
Accrued preferred dividends ....... | — | — | — | — | ( | — | — | — | ( | ||||||||
December 31, 2024 (Successor) ..... | $ | $ | $ | $( | $ | $ | $ |
Successor | Predecessor | |||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Cash Flows Used in Operating Activities | ||||||
Net loss ............................................................................................................................................... | $( | $( | $( | |||
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: | ||||||
Stock-based compensation ................................................................................................................ | ||||||
Interest income on debt securities - related party .............................................................................. | ( | ( | ||||
Change in fair value of financial liabilities ........................................................................................ | ( | |||||
Change in fair value of payables due to related parties ..................................................................... | ( | |||||
Write-off of loan commitment fee asset ............................................................................................ | ||||||
Non-cash interest expense on notes payable ...................................................................................... | ||||||
Net (gain) loss on investments ........................................................................................................... | ( | |||||
Equity method investment gain (loss) ................................................................................................ | ( | |||||
Loss on conversion of promissory notes ............................................................................................ | ||||||
Deferred income taxes ....................................................................................................................... | ( | |||||
Depreciation and amortization ........................................................................................................... | ||||||
Payment of patent installment ............................................................................................................ | ( | |||||
Non-cash rent costs ............................................................................................................................ | ||||||
Accrued unpaid interest on note payable ........................................................................................... | ||||||
Changes in operating assets and liabilities: | ||||||
Accounts receivable ........................................................................................................................... | ( | ( | ||||
Prepaid expenses and other current assets ......................................................................................... | ( | ( | ( | |||
Inventory ............................................................................................................................................ | ( | ( | ||||
Accounts payable ............................................................................................................................... | ( | |||||
Accrued employee benefits ................................................................................................................ | ||||||
Accrued expenses ............................................................................................................................... | ( | |||||
Stock-based compensation liability ................................................................................................... | ||||||
Other current liabilities ...................................................................................................................... | ( | ( | ( | |||
Obligation to issue equity .................................................................................................................. | ||||||
Other assets ........................................................................................................................................ | ( | ( | ||||
Net Cash Used in Operating Activities .......................................................................................................... | ( | ( | ( | |||
Cash Flows Provided by (Used in) Investing Activities | ||||||
Purchase of shares in equity method investee .................................................................................... | ( | |||||
Contributions to equity method investee ........................................................................................... | ( | |||||
Investment in debt securities - equity method investee ..................................................................... | ( | ( | ||||
Advances to equity method investee .................................................................................................. | ( | ( | ||||
Acquisition of property, plant and equipment ................................................................................... | ( | ( | ( | |||
Acquisition of intangible assets ......................................................................................................... | ( | |||||
Acquisition of net assets, net of cash acquired, through business combination ................................ | ||||||
Proceeds from sale of investments ..................................................................................................... | ||||||
Cash withdrawn from trust as a result of business combination ........................................................ | ||||||
Net Cash Provided by (Used in) Investing Activities ....................................................................... | ( | ( | ||||
Cash Flows Provided by Financing Activities | ||||||
Proceeds from issuance of equity, net of issuance costs .................................................................... | ||||||
Proceeds from the issuance of equity to non-controlling interest, net of issuance costs ................... | ||||||
Proceeds from the issuance of convertible promissory note .............................................................. | ||||||
Proceeds from issuance of debt securities, net of issuance costs ....................................................... | ||||||
Payment of debts ................................................................................................................................ | ( | ( | ( | |||
Receipt of Capital from Class I Unitholder ....................................................................................... | ||||||
Distributions to Stockholders ............................................................................................................. | ( | ( | ||||
Proceeds from the issuance of promissory notes to related parties .................................................... | ||||||
Repayment of promissory note .......................................................................................................... | ( | |||||
Cash Flows Provided by Financing Activities .................................................................................................. | ||||||
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash ......................................... | ( | |||||
Cash, Cash Equivalents and Restricted Cash Beginning of period .................................................... | ||||||
Cash, Cash Equivalents and Restricted Cash End of period ............................................................ | $ | $ | $ |
Successor | Predecessor | |||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Supplemental Cash Flow Information | ||||||
Cash paid for interest ................................................................................................................................. | $ | $ | $ | |||
Supplemental Disclosure of Noncash Financing Information | ||||||
Accretion of redeemable units to redemption value .................................................................................. | ||||||
Debt discount and embedded derivative upon issuance ............................................................................ | ||||||
Issuance of units to non-controlling interest in exchange of convertible promissory notes ...................... | ||||||
Conversion of working capital loans to equity method investees into investments in debt securities - related party ......................................................................................................................................... | ||||||
Transfer of liability warrants to equity warrants in the Business Combination ......................................... | ||||||
Initial recognition of loan commitment fee ................................................................................................ | ||||||
Transfer of loan commitment fee asset ...................................................................................................... |
Successor | Predecessor | |||
December 31, 2024 | December 31, 2023 | |||
Equity-method investments ...................................................................................... | $ | $ | ||
Exchange-traded investments at fair value ............................................................... | ||||
Investment in debt securities - AFS.......................................................................... | ||||
Total Investments ................................................................................................. | $ | $ |
Successor | Predecessor | |||||||
December 31, 2024 | December 31, 2023 | |||||||
Asset type | Carrying Amount | Maximum Exposure to Loss | Carrying Amount | Maximum Exposure to Loss | ||||
Equity method investment in AeroFlexx ........... | $ | $ | $ | $ | ||||
Investments in debt securities - AFS ................. | ||||||||
Due from related party ....................................... | ||||||||
Total ................................................................. | $ | $ | $ | $ |
ESG Fund | AeroFlexx | ||||||
December 31, | December 31 | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Total Assets ......................................................... | $ | $ | $ | $ | |||
Total Liabilities ................................................... | |||||||
Total Equity (Deficit) .......................................... | $ | $ | $( | $ |
ESG Fund | AeroFlexx | ||||||
Years ended December 31, | Years ended December 31, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Revenue ............................................................... | $ | $ | $ | $ | |||
Gross (Loss) Profit ............................................. | ( | ( | ( | ||||
Net Income (Loss) ............................................... | $ | $( | $( | $( |
Amortized cost | Gross unrealized gains | Fair value | |||
Investment in Debt Securities - AFS .............................................. | $ | $ | $ |
Amortized cost | Fair value | ||
Due within one year ................................................................................................... | $ | $ | |
Due after one year through five years ....................................................................... | |||
Due after five years .................................................................................................... | |||
$ | $ |
December 31, 2024 (Successor) | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Total | |||
Assets: | |||||||
Investment in debt security - AFS ....................... | $ | $ | $ | $ | |||
Liabilities: | |||||||
Earnout liability ................................................... | |||||||
WTI warrant liability | |||||||
Private placement warrant liability ..................... |
December 31, 2023 (Predecessor) | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs( Level 3) | Total | |||
Assets: | |||||||
Exchange-traded investments at FVTNI ............. | $ | $ | $ | $ | |||
Liabilities: | |||||||
Embedded derivative liability ............................. | $ | $ | $ | $ | |||
Related party payables ........................................ |
Forward Contract | Embedded Derivative Liability | Investment in debt securities - AFS | Earnout Liability | WTI Warrant Liability | |||||
Balance as of January 1, 2023 (Predecessor) .................................... | $ | $ | $ | $ | $ | ||||
Additions ............................................ | |||||||||
Change in fair value ........................... | ( | ||||||||
Balance as of December 31, 2023 (Predecessor) ..................................... | $ | $ | $ | $ | $ | ||||
Additions ............................................ | |||||||||
Settlement ........................................... | ( | ||||||||
Change in fair value ........................... | |||||||||
Balance as of October 1, 2024 (Predecessor) ..................................... | |||||||||
Balance as of October 2, 2024 (Successor) ........................................ | |||||||||
Additions ............................................ | |||||||||
Settlement ........................................... | ( | ||||||||
Change in fair value ........................... | |||||||||
Balance as of December 31, 2024 (Successor) ........................................ | $ | $ | $ | $ | $ |
Embedded derivative within 2025 Note issued August 18, 2022 with a principal balance of $ | Settlement | December 31, 2023 | |
Discount Rate .......................................................................................................... | |||
Probability of Expected Outcomes | |||
Financing .............................................................................................................. | |||
Change in control .................................................................................................. | |||
Other ..................................................................................................................... | |||
Embedded derivative within 2025 Notes issued June 7 & July 3, 2023 with an aggregate principal balance of $ | |||
Discount Rate .......................................................................................................... | |||
Probability of Expected Outcomes | |||
Financing .............................................................................................................. | |||
Change in control .................................................................................................. | |||
Other ..................................................................................................................... |
October 2, 2024 | December 31, 2024 | ||
Volatility .................................................................................................................... | |||
Time to liquidity ........................................................................................................ | |||
Discount for lack of marketability ............................................................................. | |||
Weighted average cost of capital ............................................................................... | |||
Risk-free rate ............................................................................................................. |
October 2, 2024 | December 31, 2024 | ||
Term ........................................................................................................................... | |||
Stock price ................................................................................................................. | $ | $ | |
Volatility .................................................................................................................... | |||
Risk-Free Rate ........................................................................................................... | |||
Dividend Yield .......................................................................................................... |
October 2, 2024 | |
Revenue risk premium .......................................................................................................................... | |
Revenue volatility ................................................................................................................................. |
October 2, 2024 | December 31, 2024 | |
Revenue risk premium ................................................................................................ | ||
Revenue volatility ....................................................................................................... |
October 22, 2024 | December 31, 2024 | |
Stock Price .................................................................................................................. | $ | $ |
Stock Price Volatility .................................................................................................. | ||
Credit Spread .............................................................................................................. |
Successor | Predecessor | |||||||||
Maturities | December 31, 2024 | Interest Rates | December 31, 2023 | Interest Rates | ||||||
Series 1 promissory notes .......................... | 2025 - 2026 | $ | $ | |||||||
Related party notes .................................... | 2024 - 2025 | —% | ||||||||
Convertible promissory notes .................... | ||||||||||
WTI Facility .............................................. | 2028 | |||||||||
Total Notes Payable ................................ | ||||||||||
Less: unamortized debt discount ............... | ( | ( | ||||||||
Less: current portion of related party notes payable .......................................... | ( | ( | ||||||||
Less: current portion of notes payable ....... | ( | ( | ||||||||
Total Long-term Notes .......................... | $ | $ |
Year Ending December 31, | Amount |
2025 ...................................................................................................................................................... | $ |
2026 ...................................................................................................................................................... | |
2027 ...................................................................................................................................................... | |
2028 ...................................................................................................................................................... | |
Total Debt ........................................................................................................................................... | $ |
Successor | Predecessor | |||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Principal amount ........................................................................... | $ | $ | $ | |||
Number of shares .......................................................................... |
Successor | Predecessor | |||||
Interest Rate | December 31, 2024 | December 31, 2023 | ||||
Principal amount of 1st extension promissory notes ..................... | $ | $ | ||||
Principal amount of 2nd extension promissory notes ................... | $ | $ |
Successor | Predecessor | |||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Interest attributable to contractual interest ..................................... | $ | $ | $ | |||
Interest attributable to amortization of issuance costs .................... | ||||||
Total interest expense .................................................................. | $ | $ | $ |
Successor | Predecessor | |||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Total interest expense .................................................................. | $ | $ | $ |
Successor | Predecessor | |||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Interest attributable to contractual interest .................................... | $ | $ | $ | |||
Interest attributable to amortization of implied discounts ............. | ||||||
Total interest expense ................................................................ | $ | $ | $ |
Successor | Predecessor | |||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Interest attributable to contractual interest .................................... | $ | $ | $ | |||
Interest attributable to amortization of issuance costs .................. | ||||||
Total interest expense ................................................................ | $ | $ | $ |
Successor | Predecessor | |||
December 31, 2024 | December 31, 2023 | |||
Raw materials ........................................................................................................... | $ | $ | ||
Work in process ........................................................................................................ | ||||
Finished goods .......................................................................................................... | ||||
Total inventories ..................................................................................................... | $ | $ |
Successor | Predecessor | |||
December 31, 2024 | December 31, 2023 | |||
Leasehold improvements .......................................................................................... | $ | $ | ||
Machinery & equipment ........................................................................................... | ||||
Computers & office equipment ................................................................................ | ||||
Construction in progress ........................................................................................... | ||||
Property, Plant and Equipment, Gross ............................................................... | ||||
Less: Accumulated depreciation ............................................................................... | ( | ( | ||
Property, Plant and Equipment, Net .................................................................. | $ | $ |
Successor | Predecessor | |||||
Period from October 2, 2024 through December 31, 2024 | Period from January 1 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Depreciation Expense .................................................................... | $ | $ | $ |
Innventure LLC Units | Immediately Prior to Closing | Common Stock Conversion Ratio | Common Stock Upon Closing | ||
Class B Preferred Units .................................................................. | |||||
Class B-1 Preferred Units ............................................................... | |||||
Class A Units .................................................................................. | |||||
Class C Units .................................................................................. | |||||
Total ............................................................................................... | |||||
Learn CW Shares | |||||
Learn CW Public shareholders ...................................................... | |||||
Learn CW Class B Shareholders .................................................... | |||||
Total ............................................................................................... | |||||
Less: Learn CW shares subject to clawback provisions ................. | ( | ||||
Total Common Stock Issued and Outstanding at Closing ........ |
Holdco Common Stock transferred to Innventure Members(1) ............................................................. | $ |
Contingent consideration(2) ................................................................................................................... | |
Consideration transferred ................................................................................................................. | |
Non-controlling interest(3) ..................................................................................................................... | |
Total business enterprise value ......................................................................................................... | $ |
Amount | |
Cash consideration transferred .............................................................................................................. | $ |
Add: Cash and cash equivalents acquired ............................................................................................. | |
Investing cash flow activity as a result of the Business Combination ............................................ | $ |
Amount | |
Cash proceeds from Learn CW trust account ....................................................................................... | $ |
Net cash proceeds from Series B Preferred Stock issuance .................................................................. | |
Total Innventure, Inc. cash sources ................................................................................................... | $ |
Payment of Learn CW accounts payable and accrued expenses .......................................................... | $ |
Payment of Learn CW promissory note due to Sponsor ....................................................................... | |
Payment of Innventure LLC transaction costs at Closing .................................................................... | |
Total cash uses ..................................................................................................................................... | $ |
Net cash proceeds ................................................................................................................................ | $ |
Amount | |
Assets acquired: | |
Cash and cash equivalents ................................................................................................................ | $ |
Accounts receivable ......................................................................................................................... | |
Due from related parties ................................................................................................................... | |
Inventory .......................................................................................................................................... | |
Prepaid expenses and other current assets ....................................................................................... | |
Equity method investments .............................................................................................................. | |
Investment in debt securities - AFS ................................................................................................. | |
Property, plant, and equipment ........................................................................................................ | |
Intangible assets ............................................................................................................................... | |
Other assets ...................................................................................................................................... | |
Total assets acquired: ........................................................................................................................ | $ |
Liabilities assumed: | |
Accounts payable ............................................................................................................................. | $ |
Accrued employee benefits .............................................................................................................. | |
Accrued expenses ............................................................................................................................. | |
Related party payable ....................................................................................................................... | |
Notes payable ................................................................................................................................... | |
Patent installment payable ................................................................................................................ | |
Deferred tax liability ........................................................................................................................ | |
Other liabilities ................................................................................................................................. | |
Total liabilities assumed: ................................................................................................................... | $ |
Net identifiable assets acquired ......................................................................................................... | $ |
Goodwill ............................................................................................................................................... | $ |
Amount | |
Trade names .......................................................................................................................................... | |
Customer relationships .......................................................................................................................... | |
Developed technology .......................................................................................................................... | |
Total ..................................................................................................................................................... | $ |
December 31, 2024 (Successor) | |||||||
Intangible Asset | Weighted- Average Amortization Period (years) | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | |||
Trade names ........................................................ | ( | ||||||
Customer relationships ........................................ | ( | ||||||
Developed technology ........................................ | ( | ||||||
Other finite-lived intangible assets ..................... | |||||||
Total intangible assets ....................................... | $ | $( | $ |
Amortization Expense | |
2025 ...................................................................................................................................................... | $ |
2026 ...................................................................................................................................................... | |
2027 ...................................................................................................................................................... | |
2028 ...................................................................................................................................................... | |
2029 ...................................................................................................................................................... | |
Thereafter .............................................................................................................................................. | |
Total ..................................................................................................................................................... | $ |
Number of Public Warrants | Number of Private Warrants | Number of WTI Warrants | |||
Outstanding, October 2, 2024 (Successor) ................................. | |||||
Exercised ....................................................................................... | ( | ||||
Issued .............................................................................................. | |||||
Outstanding, December 31, 2024 (Successor) ............................ |
Successor | |||||||
December 31, 2024 | |||||||
Number of Warrants | Exercise Price | Expiration Date | Balance | ||||
Private Warrants .................................................. | $ | 10/2/2029 | $ |
Successor | |||||||
December 31, 2024 | |||||||
Number of Warrants | Exercise Price | Expiration Date | Balance | ||||
WTI Warrants ..................................................... | varies | 3/31/2025 | $ |
Successor | Predecessor | |||||
Period from October 2, 2024 through December 31, 2024 | Period from January 1 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Compensation expense .................................................................. | $ | $ | $ |
Number of Shares | Weighted Average Grant Date Fair Value (per share) | ||
Granted on December 9, 2024 ................................................................................... | $ | ||
Vested ........................................................................................................................ | |||
Forfeited ..................................................................................................................... | |||
Non-vested at December 31, 2024 ............................................................................ | $ |
Number of Shares | Weighted Average Exercise Price | Weighted Average Grant Date Fair Value (per share) | |||
Granted on December 9, 2024 ........................................................ | $ | $ | |||
Vested ............................................................................................. | |||||
Exercised ........................................................................................ | |||||
Forfeited ......................................................................................... | |||||
Outstanding at December 31, 2024 ................................................ | $ | $ | |||
Exercisable at December 31, 2024 ................................................. |
Cash-settled SARs | Stock-settled SARs | ||||||||||
Number of Shares | Weighted Average Exercise Price | Weighted Average Grant Date Fair Value (per share) | Number of Shares | Weighted Average Exercise Price | Weighted Average Grant Date Fair Value (per share) | ||||||
Granted on December 9, 2024 .................................... | $ | $ | $ | $ | |||||||
Vested .................................... | |||||||||||
Exercised ............................... | |||||||||||
Forfeited ................................. | |||||||||||
Outstanding at December 31, 2024 .................................... | $ | $ | $ | $ | |||||||
Exercisable at December 31, 2024 .................................... |
Successor Period | Predecessor Period | |||||
Period from October 2, 2024 through December 31, 2024 | Period from January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Compensation expense .................................................................. | $ | $ | $ | |||
Class C units granted ..................................................................... | ||||||
Weighted average grant date fair value per share ......................... | $ | $ | $ |
Successor | Predecessor | ||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | |||
Product revenue .............................................................................. | $ | $ | $ | ||
Management fees - related party .................................................... | |||||
Consulting revenue ......................................................................... | |||||
Total revenue .................................................................................. | $ | $ | $ |
Successor | Predecessor | ||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | |||
Customer A - Related Party ............................................................ | |||||
Customer B - Related Party ............................................................ | |||||
Customer C ..................................................................................... | |||||
Customer D .................................................................................... | |||||
Customer E ..................................................................................... | |||||
Total Revenue Concentration of Major Customers ................. |
Successor | Predecessor | |||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Current Expense: ........................................................................ | ||||||
Federal ........................................................................................... | ||||||
State ............................................................................................... | ||||||
Foreign .......................................................................................... | ||||||
Total Current Expense ............................................................... | ||||||
Deferred Expense: ......................................................................... | ||||||
Federal ........................................................................................... | ( | |||||
State ............................................................................................... | ||||||
Foreign .......................................................................................... | ||||||
Total Deferred Expense .............................................................. | ( | |||||
Total Expense: ............................................................................ | $( | $ | $ |
Successor | Predecessor | |||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Pre-tax book loss ........................................................................... | $( | $( | $( | |||
Income taxes at federal statutory rate ............................................ | ( | |||||
State taxes, net of federal benefit .................................................. | ( | |||||
Tax on pre-tax earnings of corporate subsidiaries ........................ | ( | ( | ||||
Warrant liability ............................................................................ | ||||||
Non-deductible expenses .............................................................. | ||||||
Change in earnout fair value ......................................................... | ( | |||||
Other permanent differences ......................................................... | ( | ( | ||||
Change in valuation allowance ..................................................... | ||||||
R&D credit .................................................................................... | ( | |||||
Total provision (benefit) for income taxes .............................. | $( | $ | $ |
December 31, 2024 | December 31, 2023 | ||
Deferred Tax Assets: | |||
Deferred lease liabilities ............................................................................................ | $ | $ | |
Capitalized R&D expense ......................................................................................... | |||
Fixed assets and intangibles ...................................................................................... | |||
Reserves and other accruals ....................................................................................... | |||
Loss carry-forwards and other tax attributes ............................................................. | |||
Total Deferred Tax Assets ....................................................................................... | |||
Less: Valuation allowance ......................................................................................... | ( | ( | |
Net Deferred Tax Assets ........................................................................................ | $ | $ | |
Deferred Tax Liabilities: | |||
Amortization .............................................................................................................. | $( | $( | |
Investment in Partnerships ......................................................................................... | ( | ||
Right of use assets ..................................................................................................... | ( | ( | |
Total Deferred Tax Liabilities ................................................................................. | ( | ( | |
Net Deferred Tax Liabilities .................................................................................... | $( | $ |
Successor | |
October 2, 2024 through December 31, 2024 | |
Numerator: | |
Net loss attributable to Innventure, Inc. shareholders ....................................................................... | $( |
Less: Cumulative earnings to participating securities .................................................................. | |
Undistributed loss for participating securities ................................................................................ | ( |
Less: Undistributed loss attributable to participating securities | |
Net Loss attributable to common shareholders, basic and diluted ............................................ | $( |
Denominator: | |
Weighted average number of units outstanding, basic and diluted .............................................. | |
Net loss per share attributable to common shareholders, basic and diluted ........................... | $( |
Successor | |
December 31, 2024 | |
Public warrants ...................................................................................................................................... | |
Private placement warrants ................................................................................................................... | |
WTI warrants ........................................................................................................................................ | |
Series B preferred shares ...................................................................................................................... | |
Share options ......................................................................................................................................... | |
RSUs ..................................................................................................................................................... | |
SARs ..................................................................................................................................................... |
Years Ending December 31, | Amount | |
2025 ..................................................................................................................................................... | $ | |
2026 ..................................................................................................................................................... | ||
2027 ..................................................................................................................................................... | ||
2028 ..................................................................................................................................................... | ||
2029 ..................................................................................................................................................... | ||
Thereafter ............................................................................................................................................. | ||
Total .................................................................................................................................................... | $ |
Successor | Predecessor | |||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Revenue from external customers ............................................. | $ | $ | $ | |||
Interest income .............................................................................. | ||||||
Cost of sales .................................................................................. | $ | $ | $ | |||
Employee costs ............................................................................ | ||||||
Facilities, equipment & supplies ................................................. | ||||||
General and administrative ........................................................... | ||||||
Outside services ........................................................................... | ||||||
Research and development ............................................................ | ||||||
Sales and marketing ...................................................................... | ||||||
Depreciation expense * ................................................................. | ||||||
Interest expense ............................................................................. | ||||||
Income tax expense (benefit) ........................................................ | ( | |||||
Other ** ......................................................................................... | ( | |||||
Total Expenses ............................................................................. | $ | $ | $ | |||
Net Loss ........................................................................................ | $( | $( | $( |
Successor | Predecessor | |||||
October 2, 2024 through December 31, 2024 | January 1, 2024 through October 1, 2024 | Year ended December 31, 2023 | ||||
Revenues: | ||||||
Technology .................................................................................... | $ | $ | $ | |||
Other .............................................................................................. | ||||||
Elimination of management services provided to Technology ..... | ( | ( | ( | |||
Consolidated Revenues ............................................................... | $ | $ | $ | |||
Interest Expense: | ||||||
Technology .................................................................................... | $ | $ | $ | |||
Other .............................................................................................. | ||||||
Consolidated Interest Expense ................................................... | $ | $ | $ | |||
Interest Income: | ||||||
Technology .................................................................................... | $ | $ | $ | |||
Other .............................................................................................. | ||||||
Consolidated Interest Income .................................................... | $ | $ | $ | |||
Depreciation and Amortization Expense: | ||||||
Technology .................................................................................... | $ | $ | $ | |||
Other .............................................................................................. | ||||||
Consolidated Depreciation and Amortization Expense ........... | $ | $ | $ | |||
Net Loss: | ||||||
Technology .................................................................................... | $( | $( | $( | |||
Other .............................................................................................. | ( | ( | ( | |||
Consolidated Net Loss ................................................................ | $( | $( | $( | |||
Capital Expenditures: | ||||||
Technology .................................................................................... | $ | $ | $ | |||
Other .............................................................................................. | ||||||
Consolidated Capital Expenditures ........................................... | $ | $ | $ |
Amount to be paid | ||
SEC registration fee .............................................................................................................................. | $8,275.16 | |
Accounting fees and expenses ............................................................................................................... | $ | (1) |
Legal fees and expenses ........................................................................................................................ | $ | (1) |
Printing and miscellaneous expenses .................................................................................................... | $ | (1) |
Total ...................................................................................................................................................... | $ | (1) |
Exhibit Number | Description of Exhibits | |
2.1+ | ||
3.1 | ||
3.2 | ||
3.3^ | ||
3.4 | ||
4.1 | ||
4.2 | ||
4.3 | ||
4.4 | ||
4.5 |
Exhibit Number | Description of Exhibits | |
4.6 | ||
4.7 | ||
4.8^ | ||
4.9^ | ||
4.10^ | ||
4.11 | ||
5.1* | ||
10.1# | ||
10.2 | ||
10.3 | ||
10.4 | ||
10.5 | ||
10.6 | ||
10.7 | ||
10.8# | ||
10.9# | ||
10.10 |
Exhibit Number | Description of Exhibits | |
10.11 | ||
10.12 | ||
10.13 | ||
10.14 | ||
10.15**^ | ||
10.16**^† | ||
10.17 | ||
10.18 | ||
10.19 | ||
10.20 | ||
10.21 | ||
10.22^ | ||
10.23 | ||
10.24 | ||
10.25 | ||
10.26 | ||
10.27# |
Exhibit Number | Description of Exhibits | |
10.28# | ||
10.29^ | ||
10.30 | ||
10.31 | ||
10.32 | ||
10.33# | ||
10.34# | ||
10.35# | ||
10.36# | ||
10.37 | ||
10.38^ | ||
10.39^ | ||
10.40^ | ||
10.41 | ||
10.42 | ||
10.43# | ||
21.1 | ||
23.1* | ||
23.2* | ||
24.1* | ||
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB* | Inline XBRL Taxonomy Extension Lable Linkbase Document |
Exhibit Number | Description of Exhibits | |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
107* |
INNVENTURE, INC | ||
By: | /s/ Gregory W. Haskell | |
Name: | Gregory W. Haskell | |
Title: | Chief Executive Officer and Director |
Signature | Title | Date | ||
/s/ Gregory W. Haskell | Chief Executive Officer and Director (Principal Executive Officer) | April 15, 2025 | ||
Gregory W. Haskell | ||||
/s/ David Yablunosky | Chief Financial Officer and Director (Principal Financial Officer and Principal Accounting Officer) | April 15, 2025 | ||
David Yablunosky | ||||
/s/ Michael Otworth | Executive Chairman and Director | April 15, 2025 | ||
Michael Otworth | ||||
/s/ Suzanne Niemeyer | General Counsel and Director | April 15, 2025 | ||
Suzanne Niemeyer | ||||
/s/ James O. Donnally | Director | April 15, 2025 | ||
James O. Donnally | ||||
/s/ Bruce Brown | Director | April 15, 2025 | ||
Bruce Brown | ||||
/s/ Elizabeth Williams | Director | April 15, 2025 | ||
Elizabeth Williams | ||||
/s/ Daniel J. Hennessy | Director | April 15, 2025 | ||
Daniel J. Hennessy | ||||
/s/ Michael Amalfitano | Director | April 15, 2025 | ||
Michael Amalfitano |